Impact of age on choice of chemotherapy and outcome in advanced colorectal cancer
- PMID: 22119202
- DOI: 10.1016/j.ejca.2011.09.029
Impact of age on choice of chemotherapy and outcome in advanced colorectal cancer
Abstract
Background: Age is a major risk factor for development of sporadic colorectal cancer but elderly patients are underrepresented in clinical trials and are potentially offered chemotherapy less often.
Methods: Data were obtained from South Australian Clinical Registry for advanced colorectal cancer between 1st February 2006 and 9th September 2010. Patients who received chemotherapy were analysed to assess the impact of single versus combination chemotherapy and to assess the outcome in two age cohorts, age < 70 years and ≥ 70 years.
Results: Out of a total of 1745 patients in the database during this time period, 951 (54.5%) received systemic chemotherapy. 286 (30%) received first line therapy (median age 74 years) with single agent fluoropyrimidine and 643 patients (68%) received first line combination chemotherapy (median age 64 years). The median overall survival of patients receiving first line combination chemotherapy was 23.9 months compared to 17.2 months for those who received single agent fluoropyrimidine (p<0.001). Combination chemotherapy was given to 81% of patients aged < 70 years compared to 53% of those ≥ 70 years. There was no significant difference in median overall survival of patients receiving chemotherapy by age cohort, 21.3 months for age <70 years and 21.1 months for age ≥ 70 years (p = 0.4).
Conclusion: Treatment outcomes are comparable in both the elderly and younger patients. Patients who received initial combination chemotherapy were younger and had a longer median overall survival. In our study, age appeared to influence the treatment choices but not necessarily outcome.
Copyright © 2011 Elsevier Ltd. All rights reserved.
Similar articles
-
A population-based study of metastatic colorectal cancer in individuals aged ≥ 80 years: findings from the South Australian Clinical Registry for Metastatic Colorectal Cancer.Cancer. 2013 Feb 15;119(4):722-8. doi: 10.1002/cncr.27802. Epub 2012 Sep 18. Cancer. 2013. PMID: 22990939
-
Palliative chemotherapy in elderly patients with common metastatic malignancies: A Hellenic Cooperative Oncology Group registry analysis of management, outcome and clinical benefit predictors.Crit Rev Oncol Hematol. 2008 Jun;66(3):237-47. doi: 10.1016/j.critrevonc.2007.12.003. Epub 2008 Feb 1. Crit Rev Oncol Hematol. 2008. PMID: 18243010
-
Chemotherapy of metastatic colorectal cancer.Prescrire Int. 2010 Oct;19(109):219-24. Prescrire Int. 2010. PMID: 21180382 Review.
-
Randomised phase 2 trial of SIR-Spheres plus fluorouracil/leucovorin chemotherapy versus fluorouracil/leucovorin chemotherapy alone in advanced colorectal cancer.J Surg Oncol. 2004 Nov 1;88(2):78-85. doi: 10.1002/jso.20141. J Surg Oncol. 2004. PMID: 15499601 Clinical Trial.
-
Should chemotherapy be used as a treatment of advanced colorectal carcinoma (ACC) in patients over 70 years of age?Eur J Cancer. 1999 Nov;35(12):1640-9. doi: 10.1016/s0959-8049(99)00185-9. Eur J Cancer. 1999. PMID: 10674007 Review. No abstract available.
Cited by
-
Tolerability of neoadjuvant chemotherapy for esophageal cancer in elderly patients over 76 years of age.Nagoya J Med Sci. 2022 May;84(2):388-401. doi: 10.18999/nagjms.84.2.388. Nagoya J Med Sci. 2022. PMID: 35967940 Free PMC article.
-
High BRAF Mutation Frequency and Marked Survival Differences in Subgroups According to KRAS/BRAF Mutation Status and Tumor Tissue Availability in a Prospective Population-Based Metastatic Colorectal Cancer Cohort.PLoS One. 2015 Jun 29;10(6):e0131046. doi: 10.1371/journal.pone.0131046. eCollection 2015. PLoS One. 2015. PMID: 26121270 Free PMC article.
-
Real-World Adverse Effects of Capecitabine Toxicity in an Elderly Population.Drugs Real World Outcomes. 2018 Sep;5(3):161-167. doi: 10.1007/s40801-018-0138-9. Drugs Real World Outcomes. 2018. PMID: 29934933 Free PMC article.
-
Impact of intraoperative blood loss on morbidity and survival after radical surgery for colorectal cancer patients aged 80 years or older.Int J Colorectal Dis. 2016 Feb;31(2):327-34. doi: 10.1007/s00384-015-2405-5. Epub 2015 Sep 28. Int J Colorectal Dis. 2016. PMID: 26412248
-
Capecitabine and oxaliplatin combined with bevacizumab are feasible for treating selected Japanese patients at least 75 years of age with metastatic colorectal cancer.BMC Cancer. 2015 Oct 24;15:786. doi: 10.1186/s12885-015-1712-0. BMC Cancer. 2015. PMID: 26497654 Free PMC article. Clinical Trial.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical